Silvana Quaglini,Lucia Sacchi,Federico Sottotetti et al.
Silvana Quaglini et al.
The purpose of this editorial is to explore the potential and risks of using AI in the medical field, particularly in oncology. We describe the history of AI from its origins to the present day, highlighting its positive aspects and potenti...
Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL [0.03%]
XPO1抑制剂联合CD19 CAR-T细胞在TP53突变型DLBCL中的协同作用
Zhimin Bai,Xiaoyu Huang,Xinfeng Wang et al.
Zhimin Bai et al.
Introduction: Diffuse large B-cell lymphoma (DLBCL) is mostly curable by chemotherapy, but p53 mutations limit the therapeutic effect of DLBCL. Although chimeric antigen receptor (CAR) T cells have made revolutionary prog...
LDCT-based lung cancer screening and small cell lung cancer: Limited but non-negligible impact on survival. A brief report [0.03%]
基于LDCT的肺癌筛查与小细胞肺癌:对生存的影响有限但不容忽视。简要报告
Roberta Eufrasia Ledda,Federica Sabia,Camilla Valsecchi et al.
Roberta Eufrasia Ledda et al.
Low-dose computed tomography (LDCT)-based lung cancer screening (LCS) seems to have very limited impact on small cell lung cancer (SCLC) outcomes. This study aims at describing frequency and outcomes of SCLC in a large LCS population.Patien...
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching [0.03%]
从静脉注射到皮下注射的帕妥珠单抗/曲妥珠单抗在乳腺癌治疗中的临床和药学经济驱动因素及转换障碍
Mariangela Gaudio,Anna Floreani,Greta Schivardi et al.
Mariangela Gaudio et al.
PurposePatients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC imple...
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial [0.03%]
来曲唑治疗激素受体阳性低级别卵巢癌Ⅲ期临床试验的初步毒性结果分析
Alessio Carbone,Elena Biagioli,Vanda Salutari et al.
Alessio Carbone et al.
Background: Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression. ...
Abdominal specimen retrieval in endometrial cancer patients with large uteri [0.03%]
大子宫子宫内膜癌患者的腹部标本取出术
Simone Bruni,Francesco Raspagliesi,Enrico Vizza et al.
Simone Bruni et al.
Objective: Endometrial cancer surgery has a low risk of specimen fragmentation, but removing large uteri can be challenging. This study aimed to assess whether the use of minilaparotomic incision for specimen retrieval co...
Two years after the reform of Italian Ethics Committees: Time for reflection [0.03%]
意大利伦理委员会改革两年后:反思时刻
Celeste Cagnazzo,Giorgia Rocca,Franca Fagioli
Celeste Cagnazzo
The recent reform of Italian Ethics Committees (ECs), formalized between 2022 and 2023, aimed to streamline ethical oversight in clinical research by transitioning from a fragmented local system to a coordinated national framework. The new ...
Trabectedin-irinotecan as a potential therapeutic option in desmoplastic small round cell tumor: A small case series [0.03%]
特拉凡辛-伊立替康治疗间质小圆细胞瘤的潜在疗效:一例病例报告
Andrea Ferrari,Stefano Chiaravalli,Walter Ferrari Bravo et al.
Andrea Ferrari et al.
IntroductionDesmoplastic small round cell tumor (DSRCT) is a rare and aggressive mesenchymal malignancy driven by the EWS-WT1 gene fusion. Prognosis remains poor despite intensive multimodal therapy. Preclinical studies indicate that trabec...
Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers [0.03%]
塞普替尼联合cemiplimab治疗RET阳性多发性甲状腺癌伴皮肤癌患者
Laura Deborah Locati,Federica Puce,Vito Amoroso et al.
Laura Deborah Locati et al.
Background: Remarkable advancements in the therapeutic armamentarium for medullary thyroid cancer (MTC) have been observed in the last 10 years. The current understanding of driver mutations, such as RET and RAS, has enab...
Postoperative radiotherapy for stage IV breast cancer following primary tumor removal: Systematic review and meta-analysis [0.03%]
手术切除原发肿瘤的IV期乳腺癌患者术后放射治疗:系统评价和 Meta 分析
Anna Maria Merlotti,Stefania Martini,Anna Maria Vandone et al.
Anna Maria Merlotti et al.
Background: De novo metastatic breast cancer (dnMBC) is diagnosed when breast cancer has spread at presentation and accounts for 5-10% of cases. The benefit of postoperative radiotherapy (PORT) after primary tumor surgery...